New hope for Tough-to-Treat blood cancer patients
NCT ID NCT01665794
Summary
This study tested whether adding a drug called carfilzomib to two existing medications (pomalidomide and dexamethasone) could help control multiple myeloma in patients whose cancer had returned or stopped responding to previous treatments. The trial involved 25 adults who had already tried at least one other therapy. Researchers aimed to find the safest dose and see how well this combination worked to shrink tumors and delay cancer progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
University Health Network - Princess Margaret Cancer Center
Toronto, Ontario, MISG 2M9, Canada
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637-1470, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Wayne State University - Karmonos Cancer Center
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.